Symptomatic and disease-modifying therapy for the progressive ataxias

Neurologist

Volumn 10, Issue 5, 2004, Pages 275-289

  Perlman, Susan L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ataxia; Disease modifying; Rehabilitation; Treatment

Indexed keywords

ACETAZOLAMIDE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMANTADINE; ANTICOAGULANT AGENT; BACLOFEN; BUSPIRONE; CARBAMAZEPINE; CARNITINE; CREATINE; ETIRACETAM; GABAPENTIN; IMMUNOGLOBULIN; ISONIAZID; METHYLPREDNISOLONE SODIUM SUCCINATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; PREDNISONE; PRIMIDONE; PROPRANOLOL; PROTIRELIN; RITUXIMAB; SELENIUM; TOPIRAMATE; UBIDECARENONE; UNINDEXED DRUG; VALPROIC ACID; ZONISAMIDE;

ABDOMINAL PAIN; AGITATION; ALOPECIA; APLASTIC ANEMIA; APNEA; ARTHRALGIA; ATAXIA; BACKACHE; BEHAVIOR DISORDER; BLEEDING; BLOOD TOXICITY; BREATHING DISORDER; BRONCHOSPASM; BULBAR PARALYSIS; CARDIOTOXICITY; CLINICAL FEATURE; COGNITIVE DEFECT; CONFUSION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEGENERATIVE DISEASE; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISEASE COURSE; DIZZINESS; DROWSINESS; DRUG CHOICE; DRUG FATALITY; DRUG HYPERSENSITIVITY; ELECTROLYTE DISTURBANCE; EOSINOPHILIA MYALGIA SYNDROME; EPISTAXIS; EXTRAPYRAMIDAL SYMPTOM; FALLING; FATIGUE; FLAPPING TREMOR; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GLAUCOMA; HAIR DISEASE; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERKINESIA; HYPERSALIVATION; HYPERTENSION; HYPERTHYROIDISM; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; IMPOTENCE; INFECTION; INSOMNIA; IRRITABILITY; LEG EDEMA; LEUKOPENIA; LIVEDO RETICULARIS; LUPUS LIKE SYNDROME; MOOD DISORDER; MUSCLE WEAKNESS; MYOPATHY; NAIL DISEASE; NAUSEA; NEPHROLITHIASIS; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPATHY; NUTRITIONAL SUPPORT; OPTIC NERVE DISEASE; PARASOMNIA; PARESTHESIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; PSEUDOTUMOR; QUALITY OF LIFE; RASH; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SEIZURE THRESHOLD; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; SLEEP APNEA SYNDROME; SOMNOLENCE; SWEATING; TASTE DISORDER; VENOUS THROMBOEMBOLISM; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ATAXIA; CELL CYCLE; CEREBELLUM; COMPLEMENTARY THERAPIES; HUMANS; ION CHANNELS; METABOLISM, INBORN ERRORS; MITOCHONDRIA; NERVOUS SYSTEM DISEASES; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 4544244896     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000141651.35193.67     Document Type: Review

References (153)

1. Lechtenberg R. Signs and symptoms of cerebellar disease. In: R Lechtenberg, ed. Handbook of Cerebellar Diseases. New York: Marcel Dekker; 1993:31-43.
2. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain. 1998;121(Pt 4):561-579.
3. Perlman SL. Diagnostic evaluation of ataxic patients. In: SM Pulst, ed. Genetics of Movement Disorders. San Diego: Academic Press; 2003.
4. Hadjivassiliou M, Grunewald R, Sharrack B, et al. Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. Brain. 2003;126(Pt 3):685-691.
5. Shill HA, Alaedini A, Latov N, et al. Anti-ganglioside antibodies in idiopathic and hereditary cerebellar degeneration. Neurology. 2003;60: 1672-1673.
6. Hadjivassiliou M, Davies-Jones GA, Sanders DS, et al. Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry. 2003;74:1221-1224.
7. Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124: 437-443.
8. Yeh JH, Chen WH, Chen JR, et al. Miller Fisher syndrome with central involvement: successful treatment with plasmapheresis. Ther Apher. 1999;3:69-71.
9. Miyamoto K, Kato T, Watanabe H, et al. A case of paraneoplastic syndrome accompanied by two types of cancer. J Neurol Neurosurg Psychiatry. 2002;72:408-409.
10. McCrystal M, Anderson NE, Jones RW, et al. Paraneoplastic cerebellar degeneration in a patient with chemotherapy-responsive ovarian cancer. Int J Gynecol Cancer. 1995;5:396-399.
11. Go T. Intravenous immunoglobulin therapy for acute cerebellar ataxia. Acta Paediatr. 2003;92:504-506.
12. Daaboul Y, Vern BA, Blend MJ. Brain SPECT imaging and treatment with IVIg in acute post-infectious cerebellar ataxia: case report. Neurol Res. 1998;20:85-88.
13. Abele M, Weller M, Mescheriakov S, et al. Cerebellar ataxia with glutamic acid decarboxylase autoantibodies. Neurology. 1999;52:857-859.
14. Pranzatelli MR, Tate ED, Travelstead AL, et al. CSF B-Cell over-expansion in paraneoplastic opsoclonus-myoclonus: effect of rituximab, an anti-B-cell monoclonal antibody. Neurology 2003;60(Suppl 1):A395.
15. Smitt PS, Gratama JW, Shamsili S, et al. Rituximab induced depletion of circulating B cells in anti-Hu and anti-Yo associated paraneoplastic neurological syndromes. Neurology 2003;60(Suppl 1):A3.
16. Gray RG, Preece MA, Green SH, et al. Inborn errors of metabolism as a cause of neurological disease in adults: an approach to investigation. J Neurol Neurosurg Psychiatry. 2000;69:5-12.
17. Gomez C. Inherited cerebellar ataxias. In: RT Johnson, JW Griffin, JC McArthur, eds. Current Therapy in Neurologic Disease. St. Louis: Mosby; 2001:292-298.
18. Hungerbuhler JP, Meier C, Rousselle L, et al. Refsum's disease: management by diet and plasmapheresis. Eur Neurol. 1985;24:153-159.
19. Platt FM, Neises GR, Reinkensmeier G, et al. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 1997;276:428-431.
20. Platt FM, Jeyakumar M, Andersson U, et al. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis. 2001;24:275-290.
21. Jeyakumar M, Norflus F, Tifft CJ, et al. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood. 2001;97:327-329.
22. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349:1433-1441.
23. Politano L, Nigro G, Nigro V, et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 2003;22:15-21.
24. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003;3:155-168.
25. Barlow C, Dennery PA, Shigenaga MK, et al. Loss of the ataxia-telangiectasia gene product causes oxidative damage in target organs. Proc Natl Acad Sci USA. 1999;96:9915-9919.
26. Lee Y, Chong MJ, McKinnon PJ. Ataxia telangiectasia mutated-dependent apoptosis after genotoxic stress in the developing nervous system is determined by cellular differentiation status. J Neurosci. 2001;21:6687-6693.
27. Barzilai A, Rotman G, Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst). 2002;1:3-25.
28. Moreira MC, Barbot C, Tachi N, et al. The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. Nat Genet. 2001;29:189-193.
29. Takashima H, Boerkoel CF, John J, et al. Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spino-cerebellar ataxia with axonal neuropathy. Nat Genet. 2002;32:267-272.
30. Marcelain K, Navarrete CL, Bravo M, et al. [Effect of vitamin E (DL-alpha-tocopherol) on the frequency of chromosomal damage in lymphocytes from patients with ataxia telangiectasia]. Rev Med Chil. 2002;130:957-963.
31. Gatei M, Shkedy D, Khanna KK, et al. Ataxia-telangiectasia: chronic activation of damage-responsive functions is reduced by alpha-lipoic acid. Oncogene. 2001;20:289-294.
32. DiMauro S, Moraes CT. Mitochondrial encephalomyopathies. Arch Neurol. 1993;50:1197-1208.
33. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve. 1997;20:1502-1509.
34. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology. 1999;52:854-857.
35. Komura K, Hobbiebrunken E, Wilichowski EK, et al. Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr Neurol. 2003;28:53-58.
36. Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q1O reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology. 2001;57:515-518.
37. Mahoney DJ, Parise G, Tarnopolsky MA. Nutritional and exercise-based therapies in the treatment of mitochondrial disease. Curr Opin Clin Nutr Metab Care. 2002;5:619-629.
38. Gerber J, Muhlenhoff U, Lill R. An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1. EMBO Rep. 2003;4:906-911.
39. Lynch DR, Farmer JM, Balcer LJ, et al. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol. 2002;59:743-747.
40. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, et al. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet. 1999;354:477-479.
41. Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart. 2002;87:346-349.
42. Buyse G, Mertens L, Di Salvo G, et al. Idebenone treatment in Friedreich's ataxia: Neurological, cardiac, and biochemical monitoring. Neurology. 2003;60:1679-1681.
43. Schols L, Vorgerd M, Schillings M, et al. Idebenone in patients with Friedreich ataxia. Neurosci Lett. 2001;306:169-172.
44. Mariotti C, Solari A, Torta D, et al. Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial. Neurology. 2003;60:1676-1679.
45. Kelso GF, Porteous CM, Hughes G, et al. Prevention of mitochondrial oxidative damage using targeted antioxidants. Ann N Y Acad Sci. 2002;959:263-274.
46. Jauslin ML, Meier T, Smith RA, et al. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. Faseb J 2003;17: 1972-1974.
47. Richardson DR. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy? Expert Opin Invest Drugs. 2003;12:235-245.
48. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet. 2000;26:300-306.
49. Albin RL. Dominant ataxias and Friedreich ataxia: an update. Curr Opin Neurol. 2003;16:507-514.
50. Ross CA. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron. 2002; 35:819-822.
51. Schon EA, Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J Clin Invest. 2003;111:303-312.
52. Mattson MP. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med. 2003;3:65-94.
53. Kaemmerer WF, Rodrigues CM, Steer CJ, et al. Creatine-supplemented diet extends Purkinje cell survival in spinocerebellar ataxia type 1 transgenic mice but does not prevent the ataxic phenotype. Neuroscience. 2001;103:713-724.
54. Peyser CE, Folstein M, Chase GA, et al. Trial of d-alpha-tocopherol in Huntington's disease. Am J Psychiatry. 1995;152:1771-1775.
55. Group HS. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001;57:397-404.
56. Tabrizi SJ, Blamire AM, Manners DN, et al. Creatine therapy for Huntington's disease: Clinical and MRS findings in a 1-year pilot study. Neurology. 2003;61:141-142.
57. Seppi K, Mueller J, Bodner T, et al. Riluzole in Huntington's disease (HD): an open label study with one year follow up. J Neurol. 2001; 248:866-869.
58. Van Damme P, Leyssen M, Callewaert G, et al. The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci Lett. 2003;343:81-84.
59. Ikonomidou C, Stefovska V, Turski L. Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc Natl Acad Sci USA. 2000;97: 12885-12890.
60. Deigner HP, Haberkom U, Kinscherf R. Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin Investig Drugs. 2000;9:747-764.
61. Steffan JS, Thompson LM. Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases. Expert Opin Ther Targets. 2003;7:201-213.
62. Cummings CJ, Sun Y, Opal P, et al. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet. 2001;10:1511-1518.
63. Yoshida H, Yoshizawa T, Shibasaki F, et al. Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch. Neurobiol Dis. 2002;10:88-99.
64. Bonelli RM, Heuberger C, Reisecker F. Minocycline for Huntington's disease: an open label study. Neurology. 2003;60:883-884.
65. Smith DL, Woodman B, Mahal A, et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol. 2003;54:186-196.
66. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001;413:739-743.
67. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA. 2003;100:2041-2046.
68. Miller VM, Xia H, Marrs GL, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA. 2003;100:7195-7200.
69. Frontali M. Spinocerebellar ataxia type 6: channelopathy or glutamine repeat disorder? Brain Res Bull. 2001;56:227-231.
70. Piedras-Renteria ES, Watase K, Harata N, et al. Increased expression of alpha 1A Ca2+ channel currents arising from expanded trinucleotide repeats in spinocerebellar ataxia type 6. J Neurosci. 2001;21:9185-9193.
71. Kubodera T, Yokota T, Ohwada K, et al. Proteolytic cleavage and cellular toxicity of the human alpha1A calcium channel in spinocerebellar ataxia type 6. Neurosci Lett. 2003;341:74-78.
72. Jen JC, Yue Q, Karrim J, et al. Spinocerebellar ataxia type 6 with positional vertigo and acetazolamide responsive episodic ataxia. J Neurol Neurosurg Psychiatry. 1998;65:565-568.
73. Jen J. Familial episodic ataxias and related ion channel disorders. Curr Treat Options Neurol. 2000;2:429-431.
74. Yabe I, Sasaki H, Yamashita I, et al. Clinical trial of acetazolamide in SCA6, with assessment using the Ataxia Rating Scale and body stabilometry. Acta Neurol Scand. 2001;104:44-47.
75. Lubbers WJ, Brunt ER, Scheffer H, et al. Hereditary myokymia and paroxysmal ataxia linked to chromosome 12 is responsive to acetazolamide. J Neurol Neurosurg Psychiatry. 1995;59:400-405.
76. Mori M, Adachi Y, Mori N, et al. Double-blind crossover study of branched-chain amino acid therapy in patients with spinocerebellar degeneration. J Neurol Sci. 2002;195:149-152.
77. Sakai T. Effects of tetrahydrobiopterin on ataxia in Machado-Joseph disease may be based upon the theory of 'cerebellar long-term depression'. Med Hypotheses. 2001;57:180-182.
78. Sakamoto N, Ohshima K, Montermini L, et al. Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J Biol Chem. 2001;276:27171-27177.
79. Sakamoto N, Larson JE, Iyer RR, et al. GGA*TCC-interrupted triplets in long GAA*TTC repeats inhibit the formation of triplex and sticky DNA structures, alleviate transcription inhibition, and reduce genetic instabilities. J Biol Chem. 2001;276:27178-27187.
80. Oertel WH. Neurotransmitters in the cerebellum. Scientific aspects and clinical relevance. In: Harding AE, Deufel T, ed. Inherited Ataxias. New York: Raven Press; 1993:33-75.
81. Perlman SL. Cerebellar Ataxia. Curr Treat Options Neurol. 2000;2: 215-224.
82. Peterson PL, Saad J, Nigro MA. The treatment of Friedreich's ataxia with amantadine hydrochloride. Neurology. 1988;38:1478-1480.
83. Filla A, De Michele G, Orefice G, et al. A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia. Can J Neurol Sci. 1993;20:52-55.
84. Botez MI, Botez-Marquard T, Elie R, et al. Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study. J Neurol Neurosurg Psychiatry. 1996;61:259-264.
85. Friedman JH. Machado-Joseph disease/spinocerebellar ataxia 3 responsive to buspirone. Mov Disord. 1997;12:613-614.
86. Lou JS, Goldfarb L, McShane L, et al. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol. 1995;52:982-988.
87. Trouillas P, Xie J, Adeleine P, et al. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. Arch Neurol. 1997;54:749-752.
88. Trouillas P, Brudon F, Adeleine P. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Arch Neurol. 1988;45:1217-1222.
89. Trouillas P, Serratrice G, Laplane D, et al. Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study. Arch Neurol. 1995;52:456-460.
90. Gazulla JE JM, Benavente I, Tordesillas C. Improvement of ataxic signs in cortical cerebellar atrophy with the GABAergic drug gabapentin. Neurology 2003;60(Suppl 1):A472.
91. Sobue I, Takayanagi T, Nakanishi T, et al. Controlled trial of thyrotropin-releasing hormone tartrate in ataxia of spinocerebellar degenerations. J Neurol Sci. 1983;61:235-248.
92. Filla A, De Michele G, Di Martino L, et al. [Chronic experimentation with TRH administered intramuscularly in spinocerebellar degeneration. Double-blind cross-over study in 30 subjects]. Riv Neurol. 1989; 59:83-88.
93. Waragai M, Ogawara K, Takaya Y, et al. [Efficacy of TRH-T for spinocerebellar degeneration-the relation between clinical features and effect of TRH therapy]. Rinsho Shinkeigaku. 1997;37:587-594.
94. Shirasaki H, Ishida C, Nakajima T, et al. [A quantitative evaluation of spinocerebellar degeneration by an acoustic analysis-the effect of taltirelin hydrate on patients with Machado-Joseph disease]. Rinsho Shinkeigaku. 2003;43:143-148.
95. Fillyaw MJ, Ades PA. Endurance exercise training in Friedreich ataxia. Arch Phys Med Rehabil. 1989;70:786-788.
96. Armutlu K, Karabudak R, Nurlu G. Physiotherapy approaches in the treatment of ataxic multiple sclerosis: a pilot study. Neurorehabil Neural Repair. 2001;15:203-211.
97. Perlmutter E, Gregory PC. Rehabilitation treatment options for a patient with paraneoplastic cerebellar degeneration. Am J Phys Med Rehabil. 2003;82:158-162.
98. Balliet R, Harbst KB, Kim D, et al. Retraining of functional gait through the reduction of upper extremity weight-bearing in chronic cerebellar ataxia. Int Rehabil Med. 1987;8:148-153.
99. Cattaneo D, Cardini R. Computerized system to improve voluntary control of balance in neurological patients. Cyberpsychol Behav. 2001; 4:687-694.
100. Gillen G. Improving mobility and community access in an adult with ataxia. Am J Occup Ther. 2002;56:462-466.
101. DiMauro S. Exercise intolerance and the mitochondrial respiratory chain. Ital J Neurol Sci. 1999;20:387-393.
102. Vorgerd M, Schols L, Hardt C, et al. Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromuscul Disord. 2000;10:430-435.
103. Lambert D, Waters CH. Essential tremor. Curr Treat Options Neurol. 1999;1:6-13.
104. Averbuch-Heller L. Acquired nystagmus. Curr Treat Options Neurol. 1999;1:68-73.
105. Tusa RJ. Nystagmus: diagnostic and therapeutic strategies. Semin Ophthalmol. 1999;14:65-73.
106. Sechi GP, Pirisi A, Agnetti V, et al. Efficacy of carbamazepine on cerebellar tremors in patients with superior cerebellar artery syndrome. J Neurol. 1989;236:461-463.
107. Biary N, Koller W. Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology. 1987;37:471-474.
108. Koller WC, Glatt S, Biary N, et al. Essential tremor variants: effect of treatment. Clin Neuropharmacol. 1987;10:342-350.
109. Onofrj M, Thomas A, Paci C, et al. Gabapentin in orthostatic tremor: results of a double-blind crossover with placebo in four patients. Neurology. 1998;51:880-882.
110. Hallett M. Isoniazid and action tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1985;48:957.
111. Hallett M, Lindsey JW, Adelstein BD, et al. Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis. Neurology. 1985;35:1374-1377.
112. Agarwal P, Frucht SJ. Myoclonus. Curr Opin Neurol. 2003;16:515-521.
113. Rice GP, Lesaux J, Vandervoort P, et al. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry. 1997;62:282-284.
114. Gbadamosi J, Buhmann C, Moench A, et al. Failure of ondansetron in treating cerebellar tremor in MS patients-an open-label pilot study. Acta Neurol Scand. 2001;104:308-311.
115. Bier JC, Dethy S, Hildebrand J, et al. Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study. J Neurol. 2003;250:693-697.
116. Sechi G, Agnetti V, Sulas FM, et al. Effects of topiramate in patients with cerebellar tremor. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1023-1027.
117. Sotaniemi K. Valproic acid in the treatment of nonepileptic myoclonus. Arch Neurol. 1982;39:448-449.
118. Borggreve F, Hageman G. A case of idiopathic palatal myoclonus: treatment with sodium valproate. Eur Neurol. 1991;31:403-404.
119. Meldrum BS. Drugs acting on amino acid neurotransmitters. Adv Neurol. 1986;43:687-706.
120. Takigawa T, Mima T, Saida K, et al. [A case of cortical reflex myoclonus manifesting tremor]. Rinsho Shinkeigaku. 1997;37:1006-1009.
121. Pacchetti C, Mancini F, Bulgheroni M, et al. Botulinum toxin treatment for functional disability induced by essential tremor. Neurol Sci. 2000;21:349-353.
122. Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001;56:1523-1528.
123. Shiga Y, Tsuda T, Itoyama Y, et al. Transcranial magnetic stimulation alleviates truncal ataxia in spinocerebellar degeneration. J Neurol Neurosurg Psychiatry. 2002;72:124-126.
124. Shimizu H, Tsuda T, Shiga Y, et al. Therapeutic efficacy of transcranial magnetic stimulation for hereditary spinocerebellar degeneration. Tohoku J Exp Med. 1999;189:203-211.
125. Bryant JA, De Salles A, Cabatan C, et al. The impact of thalamic stimulation on activities of daily living for essential tremor. Surg Neurol 2003;59:479-484; discussion 484-475.
126. Halmagyi GM, Rudge P, Gresty MA, et al. Treatment of periodic alternating nystagmus. Ann Neurol. 1980;8:609-611.
127. Lee MS, Lessell S. Lithium-induced periodic alternating nystagmus. Neurology. 2003;60:344.
128. Averbuch-Heller L, Tusa RJ, Fuhry L, et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol. 1997;41:818-825.
129. Yamamoto K, Fukusako T, Nogaki H, et al. [Multiple system atrophy with macro square wave jerks and pendular nystagmus]. Rinsho Shinkeigaku. 1992;32:1261-1265.
130. McConnell HW, Darlington CL, Smith PF, et al. Hereditary cerebellar degeneration with downbeat nystagmus. A case and it's treatment. Acta Neurol Scand. 1990;81:423-426.
131. Young YH, Huang TW. Role of clonazepam in the treatment of idiopathic downbeat nystagmus. Laryngoscope. 2001;111:1490-1493.
132. Fabre K, Smet-Dieleman H, Zeyen T. Improvement of acquired pendular nystagmus by gabapentin: case report. Bull Soc Belge Ophtalmol 2001:43-46.
133. Williams DP, Troost BT, Rogers J. Lithium-induced downbeat nystagmus. Arch Neurol. 1988;45:1022-1023.
134. Macleod AD. Ondansetron in multiple sclerosis. J Pain Symptom Manage. 2000;20:388-391.
135. Schmitt LG, Shaw JE. Alleviation of induced vertigo. Therapy with transdermal scopolamine and oral meclizine. Arch Otolaryngol Head Neck Surg. 1986;112:88-91.
136. Leigh RJ, Burnstine TH, Ruff RL, et al. Effect of anticholinergic agents upon acquired nystagmus: a double-blind study of trihexyphenidyl and tridihexethyl chloride. Neurology. 1991;41:1737-1741.
137. Lauter JL, Lynch O, Wood SB, et al. Physiological and behavioral effects of an antivertigo antihistamine in adults. Percept Mot Skills. 1999;88:707-732.
138. Lawden MC, Bronstein AM, Kennard C. Repetitive paroxysmal nystagmus and vertigo. Neurology. 1995;45:276-280.
139. Strupp M, Schuler O, Krafczyk S, et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: A placebo-controlled study. Neurology. 2003;61:165-170.
140. Carlow TJ. Medical treatment of nystagmus and ocular motor disorders. Int Ophthalmol Clin. 1986;26:251-264.
141. Baloh RW. Approach to the dizzy patient. Baillieres Clin Neurol. 1994;3:453-465.
142. Tokumasu K, Fujino A, Noguchi H. Prolonged dysequilibrium in three cases with vestibular neuronitis: efficacy of vestibular rehabilitation. Acta Otolaryngol Suppl. 1993;503:39-46.
143. Wan J, Baloh RW, Jen JC. Mechanism of action of acetazolamide in treatment of episodic ataxia type 2. Neurology 2003;60(Suppl 1):A330.
144. Jen JC, Baloh RW. Genetics of episodic ataxia. Adv Neurol. 2002;89: 459-461.
145. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34:2323-2330.
146. Gabelli C. Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions. Curr Med Res Opin. 2003;19:69-82.
147. Corey-Bloom J. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int J Clin Pract. 2003;57:219-223.
148. Bentue-Ferrer D, Tribut O, Polard E, et al. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs. 2003;17:947-963.
149. Sandoval C, Swift M. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med Pediatr Oncol. 1998;31:491-497.
150. Sharma JC, MacLennan WJ. Causes of ataxia in patients attending a falls laboratory. Age Ageing. 1988;17:94-102.
151. O'Mahony D, Foote C. Prospective evaluation of unexplained syncope, dizziness, and falls among community-dwelling elderly adults. J Gerontol A Biol Sci Med Sci. 1998;53:M435-M440.
152. Sobel KG, McCart GM. Drug use and accidental falls in an intermediate care facility. Drug Intell Clin Pharm. 1983;17:539-542.
153. Anderson FA Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation. 107(23 Suppl 1):19-16, 2003.